

1 **Adherence inhibition of enteropathogenic *Escherichia coli* by chitooligosaccharides with**
2 **specific degrees of acetylation and polymerization**

3

4 Maria-Isabel Quintero¹, Berit Bjugan Aam², John Rupnow¹, Morten Sørli², Vincent G.H.
5 Eijsink², Robert W. Hutkins^{1*}

6

7 ¹Department of Food Science and Technology, University of Nebraska, Lincoln, NE 68583-
8 0919, USA.

9 ² Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life
10 Sciences, P.O. Box 5003, N-1432 Aas, Norway

11

12 *Correspondence to Robert Hutkins, Department of Food Science and Technology, University of
13 Nebraska, 338 Food Industry Complex, Lincoln, NE 68583-0919. USA.

14 Phone: (402) 472-2820; Fax (402) 472-1693; E-mail: rhutkins1@unl.edu

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 **Abstract**

33 Some prebiotic oligosaccharides are known to act as molecular decoys by inhibiting
34 pathogen adherence to epithelial cells. The present study was aimed at analyzing whether
35 chitooligosaccharides (CHOS), i.e. oligomers of D-glucosamine and N-acetyl-D-glucosamine,
36 have such anti-adherence activity. CHOS of varied degree of polymerization (DP) and fraction of
37 acetylation (F_A) were produced. Adherence of enteropathogenic *Escherichia coli* (EPEC) to the
38 surface of a human HEp-2 cell line was studied by adding bacteria to HEp-2 cells grown on glass
39 coverslips, in the absence or presence of the various CHOS fractions. Adherence was assessed by
40 microscopic counting of bacteria and cells. The results show that CHOS inhibit adherence of
41 EPEC to HEp-2 cells by more than 90%. This effect is greater than that obtained with other
42 oligosaccharides, such as galactooligosaccharides, applied at the same concentrations.

43

44 **Abbreviations**

45 Chitooligosaccharides (CHOS), degree of polymerization (DP), enteropathogenic *Escherichia*
46 *coli* (EPEC), fraction of acetylation (F_A), tryptic soy broth (TSB), tryptic soy agar (TSA),
47 minimal essential medium (MEM)

48

49 **Keywords**

50 Prebiotics, adherence, chitooligosaccharides, chitosan, chitinase, chitosanase

51

52 **Highlights**

- 53 1. CHOS with defined degrees of polymerization and acetylation were produced.
- 54 2. CHOS inhibits adhesion of *E. coli* to HEp-2 cells.
- 55 3. Anti-adherence activity increases with decreasing F_A of the CHOS.
- 56 4. DP does not seem to have an effect on antiadherence.
- 57 5. CHOS could be added to foods as a prophylactic treatment to prevent EPEC infections.

58

59

60

61

62

63 1. Introduction

64 Prebiotics were originally defined more than 15 years ago as “non-digestible food
65 ingredient(s) that beneficially affect the host by selectively stimulating the growth and/or activity
66 of one or a limited number of bacteria in the colon, and thus improve host health” (Gibson &
67 Roberfroid, 1995). Despite slight modifications of this definition (Roberfroid, 2007),
68 establishing a substance as a prebiotic still depends on the ability of that substance to produce
69 positive changes in the gut microbiota. Recently, it has been suggested that some prebiotic
70 oligosaccharides exert their effects by directly protecting the host from pathogens. Specifically,
71 galactooligosaccharides, mannan-oligosaccharides, and pectic oligosaccharides have been shown
72 to interfere with the ability of pathogenic bacteria to attach to the surface of host tissues (Ganan
73 et al., 2010; Ghosh & Mehla, 2012; Kunz et al., 2000; Shoaf et al., 2006). For most microbial
74 enteric pathogens, the first step in the infection process is adherence to the epithelial cells that
75 line the intestinal tract. Adherence is generally mediated in these bacteria via expression of
76 lectin-like adhesins that recognize carbohydrate-containing receptor sites on the surfaces of host
77 epithelial cells (Ofek & Beachey, 1978; Ofek, Hasty, & Doyle, 2003). Accordingly, adherence
78 inhibition may occur in the presence of substances that interfere with the lectin-receptor
79 interaction, for example, by prebiotic oligosaccharides that resemble the glyco-moieties of the
80 host receptor sites. Thus, strategies based on preventing or inhibiting pathogen adherence could
81 be effective at reducing infections and the subsequent onset of disease (Bavington & Page, 2005;
82 Klemm, Vejborg, & Hancock, 2010; Shoaf et al., 2006).

83
84 One group of oligosaccharides that has attracted considerable research and commercial
85 interest due to their biological properties are the chitooligosaccharides (CHOS). CHOS are
86 produced enzymatically or chemically from chitosan, linear heteropolymers of β (1 \rightarrow 4) linked
87 *N*-acetyl-D-glucosamine (GlcNAc) and its deacetylated counterpart D-glucosamine (GlcN).
88 Chitosans may have varying compositions, usually indicated by the fraction of acetylation (F_A).
89 Soluble chitosans are produced from insoluble chitin by partial or complete *N*-deacetylation,
90 either by homogenous (Sannan, Kurita, & Iwakura, 1975) or by heterogeneous deacetylation
91 (Rigby, 1934). Chitin is an abundant natural product found in nature as a structural component of
92 the cell wall of fungi and yeasts and in the exoskeletons of insects and arthropods (e.g., crabs,
93 lobsters and shrimps). Chitosan has a wide range of applications (Alishahi & Aider, 2011;

94 Jayakumar et al., 2010; R. Muzzarelli, 1996), including its use as an antimicrobial agent
95 (Devlieghere, Vermeulen, & Debevere, 2004; Helander et al., 2001; Liu et al., 2004; Mellegård
96 et al., 2011; Rabea et al., 2003; Tsai et al., 2002).

97

98 Chitosan can be hydrolyzed by chitinases or chitosanases to give CHOS (Heggset et al.,
99 2010, 2012; Heggset et al., 2009; Sørbotten et al., 2005). These hydrolytic enzymes vary with
100 respect to their specific cleavage sites, which are determined by sequences in heteropolymers of
101 GlcNAc and GlcN. Thus, different combinations of chitosans (varying in F_A) and hydrolytic
102 enzymes (varying in sequence specificity) will yield CHOS differing in both length and sequence
103 features (Aam et al., 2010). The resulting CHOS are defined by their F_A , their average degree of
104 polymerization (DP_n) and their sequence, i.e. the pattern of *N*-acetylated sugar residues (P_A).
105 The DP_n is related to α , a parameter that indicates the degree of scission, where $\alpha = 1/DP_n$.
106 Complete conversion of chitosan to dimers ($DP_n = 2$) would yield an α value of 0.50. Methods
107 exist to separate CHOS by DP (e.g., size exclusion chromatography (Sørbotten et al., 2005)) and
108 by charge (e.g., cation exchange chromatography (Haebel, Bahrke, & Peter, 2007)). The latter is
109 based on the fraction of deacetylated residues.

110 CHOS possess a wide range of bioactivities including antifungal, antibacterial, and anti-
111 angiogenesis effects, as well as beneficial effects on wound healing and as vectors in gene
112 therapy (Aam et al., 2010; Benhabiles et al., 2012; Muzzarelli, 2005; Wu et al., 2012; Xia et al.,
113 2011) . Chitosan and CHOS are biodegradable and are considered non-toxic (Kean & Thanou,
114 2010); therefore, these compounds have a variety of potential applications in food (No et al.,
115 2007). There is evidence that CHOS ($DP < 30$, $F_A 0.01 - 0.12$) may be prebiotic, enhancing
116 growth of *Bifidobacterium* and *Lactobacillus* strains in cell cultures (Lee et al., 2002; Simunek et
117 al., 2010). This effect is apparently dependent on F_A , since Fernandes *et al.* (Fernandes et al.,
118 2012) reported that CHOS with similar DP but higher F_A (0.35) did not stimulate growth of
119 selected strains of bifidobacteria and lactobacilli.

120 Although pathogen adherence by CHOs has received relatively little attention, one
121 previous study showed that a non-defined CHOS mixture of $F_A 0.03$ and $DP_n \sim 4$ inhibited
122 adherence of three different strains of enteropathogenic *Escherichia coli* (EPEC) on HT-29 cells
123 (Rhoades et al., 2006). It is now possible, however, to produce more defined CHOS fractions

124 and to assess these fractions for anti-adherence activity. Thus, the main objective of the present
125 study was to test CHOS with different F_A and DP for their ability to inhibit adherence of EPEC,
126 a widely recognized enteric pathogen, on tissue culture cells.

127

128 **2. Materials and Methods**

129 **2.1 Preparation of CHOS**

130 Three chitosans with different F_A were enzymatically hydrolyzed. A chitosan with
131 $F_{A0.15}$ (KitoNor from Norwegian Chitosan, Gardermoen, Norway) and a chitosan with $F_{A0.3}$
132 (Heppe Medical Chitosan GmbH, Halle, Germany) were hydrolyzed with purified recombinant
133 chitosanase ScCsn46A from *Streptomyces coelicolor* A3(2) (Heggset et al., 2010). A $F_{A0.6}$
134 chitosan was prepared by homogenous deacetylation of chitin from shrimp shells (Chitonor,
135 Senjahopen, Norway) (Sannan et al., 1975). This $F_{A0.6}$ chitosan was hydrolysed with purified
136 recombinant ChiB from *Serratia marcescens* (Bruberg et al., 1995; Sørbotten et al., 2005). The
137 F_A of the chitosans before enzymatic hydrolysis, and the degree of scission (α) after degradation
138 were determined by $^1\text{H-NMR}$ using a Varian Gemini instrument at 300 MHz (Sørbotten et al.,
139 2005; Vårum et al., 1991).

140

141 The $F_{A0.6}$ chitosan was soluble in water, whereas the $F_{A0.15}$ and $F_{A0.3}$ chitosans
142 required 0.5 % acid to dissolve. All three chitosans were dissolved/suspended in buffer (40 mM
143 NaAc, 100 mM NaCl, pH 5.5) to a concentration of 10 mg/mL. Then, 0.5 % (v/v) 12 M HCl
144 was added to the $F_{A0.15}$ and $F_{A0.3}$ chitosans samples, and after the chitosan was dissolved, the
145 pH was adjusted to 5.5 with 6 M NaOH. Enzymes were added to pre-warmed chitosan solutions
146 to a final concentration of 0.5 $\mu\text{g}/\text{mg}$ chitosan and the reactions, with a final chitosan
147 concentration of approximately 9.8 mg/ml, were incubated at 37°C with shaking (225 rpm).
148 Reactions were stopped by decreasing the pH to 2.5 with HCl. The CHOS samples were filtered
149 through Filtropur S 0.2 μm sterile filters (Sarstedt, Germany), lyophilized, and resuspended in
150 the size exclusion chromatography (SEC) mobile phase to a concentration of 20 mg/mL prior to
151 separation on SEC.

152

153 **2.2 Separation of CHOS**

154 The CHOS were separated by size exclusion chromatography (SEC) on three XK 26
155 columns packed with Superdex™ 30 prep grade (GE Healthcare) coupled in series with an
156 overall dimension of 2.6 cm × 180 cm. The mobile phase (150 mM NH₄Ac, pH 4.6) was run at a
157 constant flow of 0.8 mL/min (Sørbotten et al., 2005). The column eluent was monitored using an
158 RI detector (Gilson model 133). In each run 100 mg of chitosan hydrolysate was applied (i.e. 5
159 mL) and 3.2 ml fractions were collected. Identification of oligomers in the fractions was
160 performed with MALDI-TOF-MS. The fractions were dialyzed with Float-A-Lyzers (MWCO
161 100-500 Da, SpectrumLabs) to remove salts, sterile filtrated and lyophilized. Prior to use, the
162 CHOS were dissolved in sterile distilled water.

163 To limit the number of assays, initial experiments were done with chitosan hydrolysates
164 containing mixtures of CHOS. In this case, dried material was resuspended in sterile water to a
165 final volume of 1 mL (final concentration varied according to the amount available of each
166 sample). For other experiments, samples were diluted to a final concentration of 16 mg/mL.

167

168 **2.3 Strains and Organisms**

169 EPEC strain E2348/69 (O127:H6) was used as a model organism for the anti-adherence
170 experiments. Before each experiment, cells from frozen stocks were plated on tryptic soy agar
171 (TSA; Difco) and grown overnight at 37°C. A single colony was then inoculated into 10 ml of
172 tryptic soy broth (TSB; Difco) and incubated overnight at 37°C without shaking. Overnight
173 cultures were used to inoculate (1% v/v) minimal essential medium (MEM; Hyclone)
174 supplemented with 10% (v/v) fetal bovine serum (FBS). MEM was pre-equilibrated overnight at
175 tissue culture conditions (5% CO₂, 95% relative humidity, 37°C). The cells were then incubated
176 for 80 min at 37°C, aerobically prior to the start of the experiment.

177

178 **2.4 Tissue Culture Cells**

179 HEp-2 cells were grown in 75 cm² tissue culture flasks containing 25 ml of MEM (pH
180 7.4) supplemented with 10% FBS in a CO₂ incubator at tissue culture conditions. Confluent
181 HEp-2 cells were harvested by removing MEM and washing the cells once with PBS.
182 Subsequently, 0.5 ml of a 0.25% Trypsin-EDTA solution was added followed by a 10 minute
183 incubation at tissue culture conditions. After incubation, 0.5 ml of FBS was added to inactivate
184 the trypsin. Cells were then seeded onto 12 mm diameter glass coverslips in 24-well tissue

185 culture plates at approximately 3.6×10^5 cells per well, and 500 μ l of MEM supplemented with
186 10% FBS was added to each well. Plates were incubated under tissue culture conditions for about
187 20 hours prior to the start of each experiment. Cells were checked before the experiment under
188 an inverted microscope to make sure they had reached about 70% confluency.

189

190 **2.5 Anti-adherence Assays**

191 CHOS dissolved in sterile water were mixed with bacterial cultures (approx. 10^8 cells per
192 ml in MEM supplemented with 10% FBS) to final concentrations of 16 mg/ml CHOS, prior to
193 addition to the tissue culture cells. A total of 14 fractions were analyzed - three CHOS mixtures
194 resulting from enzymatic hydrolysis of three different chitosans ($F_{A0.15}$, $F_{A0.3}$, and $F_{A0.6}$) and
195 11 fractions derived from hydrolyzed $F_{A0.15}$ chitosan by size exclusion. In addition, a mixture
196 of *N*-acetyl-D-glucosamine (Sigma) and D-glucosamine (Sigma) (15:85) was used as a control.
197 We were not able to test the non-hydrolyzed chitosans, due to the viscous nature of the chitosan
198 solutions. Sterile water was also used as a control. The standard CHOS concentration of 16
199 mg/mL was used because previous experiments with galactooligosaccharides had shown this
200 concentration to be effective in inhibiting adherence of EPEC (Shoaf et al., 2006). However, for
201 some of the fractions the amount of material was limited, and the concentration used was
202 significantly lower.

203

204 After addition of the bacteria-CHOS mixtures to tissue culture cells, the plates were
205 incubated for 30 minutes at tissue culture conditions (as described above). The wells were then
206 washed five times with phosphate buffered saline (PBS) to remove non-adhered bacteria. Cells
207 were then fixed with 100% methanol and stained with 10% Geimsa. Glass coverslips with
208 stained cells were mounted on microscope slides to be analyzed under the microscope. Fifteen
209 pictures were obtained for each cover slip and images were analyzed with ImageJ software.
210 Bacterial clusters and HEp-2 cells were counted per image to obtain a ratio of bacterial
211 clusters/HEp-2 cell. Experiments were performed in duplicate and replicated once (n=4).

212

213 **3. Results**

214 **3.1 Production, separation and characterization of CHOS**

215 In the initial experiments, chitosans with $F_A0.15$ and $F_A0.3$ were enzymatically
216 hydrolyzed with chitosanase SnCsn46A from *Streptomyces coelicolor* A3(2) to $\alpha = 0.22$ and
217 0.25 , respectively (corresponding to DP_n values of 4.5 and 4.0 , respectively). The $F_A0.6$ chitosan
218 was enzymatically hydrolysed by ChiB from *Serratia marcescens* to $\alpha = 0.19$ (DP_n 5.3). The α
219 values were determined by NMR as described previously (Wu et al., 2012) and SEC
220 chromatograms of the samples (not shown) confirmed that, as expected, the majority of the
221 CHOS was in the DP 2-20range.

222
223 Since the $F_A0.15$ sample was the most inhibitory in the initial experiments (Fig. 3;
224 discussed below), a new hydrolysis reaction was set up ($\alpha = 0.16$, DP_n 6.3) and the CHOS were
225 separated into single fractions (DP 3 – DP12) and one fraction with DP > 12 and a DP_n of 25
226 (Fig. 1A). Fig. 1B and 1C show the MALDI-TOF-MS spectra of the individual DP3-DP12
227 fractions and demonstrate that the various fractions are quite homogeneous in terms of DP. The
228 mass spectra also give an impression of the F_A distributions within the samples. For example the
229 DP4 fraction contains primarily D_4 and D_3A_1 , the DP6 fraction contains D_6 , D_5A_1 and D_4A_2 ,
230 and the DP12 fraction contains D_{12} and $D_{11}A_1$, $D_{10}A_2$, D_9A_3 and D_8A_4 .

231
232 **3.2 Inhibition of EPEC adherence by CHOS mixtures with $F_A0.15$, $F_A0.3$ and**
233 **$F_A0.65$**

234 The non-separated hydrolysates of chitosans with $F_A0.15$, $F_A0.3$, and $F_A0.65$, were tested
235 for their ability to inhibit EPEC adherence at a concentration of 16 mg/ml, a concentration used
236 in previous studies for other prebiotic oligosaccharides (Quintero et al., 2011; Shoaf et al., 2006).
237 The three samples significantly inhibited adherence (see microscopic image in Fig. 2), by as
238 much as 92%, 84% and 75%, respectively. The $F_A0.15$ CHOS sample gave the highest
239 inhibition; its effect was significantly different from the effect of the $F_A0.65$ sample ($p < 0.05$),
240 but not from the effect of $F_A0.3$ sample (Fig. 3). Non-hydrolyzed chitosans could not be tested
241 because the high viscosity of the chitosan solutions interfered with adherence experiments.
242 Bacterial motility is reduced in highly viscous solutions, resulting in obstruction of bacteria from
243 coming in contact with the tissue culture cells.

244
245 **3.3 Inhibition of EPEC adherence by purified CHOS fractions**

246 Single fractions of CHOS purified from hydrolyzed $F_A0.15$ chitosan as described above
247 (Fig. 1) were then tested in the same EPEC adherence assay. The fractions tested were single
248 fractions of DP3 to DP12, and a mixture with $DP > 12$ and $DP_n = 25$. Typical results are shown in
249 Figure 4. All CHOS fractions significantly inhibited adherence compared to the control, reaching
250 inhibition levels of close to 100 % for CHOS with DP6 and higher. Notably, adherence was not
251 inhibited by addition of a 15:85 mixture of the monomers, GlcNAc and GlcN, showing that the
252 oligomeric nature of the sugars is essential for the inhibitory effect.

253

254 **3.4 Growth of EPEC in the presence of CHOS, GlcNAc and GlcN**

255 EPEC was grown in TSB medium containing monomers of GlcNAc, GlcN, and a 15:85
256 mixture of these sugars, all at a concentration of 16 mg/ml (i.e. the same concentration used in
257 the CHOS anti-adherence assays). Growth of EPEC was not impaired by the presence of any of
258 these monomers or the mixture (Fig. 5). A similar experiment with one of the CHOS fractions
259 also showed that growth of EPEC was unaffected by CHOS (data not shown).

260

261 **4. Discussion**

262 The use of molecular decoys as anti-adherence agents was proposed more than a decade
263 ago (Andersson et al., 1986; Cravioto et al., 1991; Ebrahim, 1997; Ofek & Beachey, 1978). In
264 recent years, several food grade prebiotic oligosaccharides and plant extracts have been tested for
265 their ability to inhibit pathogen adherence to the surface of intestinal epithelial cells. In a
266 previous study, we showed that galactooligosaccharides inhibited EPEC adherence by up to 65%
267 under conditions similar to those used in the present study (Shoaf et al., 2006). Interestingly, the
268 present results indicate that CHOS, especially those with low F_A , are more effective inhibitors of
269 EPEC adherence than GOS, given that inhibition reached almost 100% for some of the fractions
270 tested.

271

272 Our results also showed that chitosans with different F_A , but similar DP_n (4.0 – 5.3) had
273 comparable adherence inhibition activities, with low F_A being the most effective (Fig. 3). Thus,
274 the glucosamine content, which affects charge density due to the titratable amino group of this
275 sugar, appears to affect the activity of CHOS against EPEC adherence. However, adherence

276 inhibition was not related to DP, as CHOS fractions purified from a hydrolyzed FA0.15 chitosan,
277 but with varying DP's, ranging from 3 to greater than 12, all inhibited adherence by up to 99%.

278
279 The anti-adherence property of oligosaccharides has been attributed to the similarity
280 between the oligosaccharide structure and cell surface receptor to which bacteria attach prior to
281 colonization. Via a phenomenon known as phase variation (Thanassi, 2011), bacteria can
282 modulate adhesin expression, depending, in part, on the available receptors expressed by the host
283 cells. This may account for why some oligosaccharides are effective in inhibiting adherence of
284 particular pathogens whereas others are not affected. Moreover, the molecular interaction
285 between oligosaccharides and bacterial adhesins varies among different pathogens, and in some
286 cases among different strains (Quintero et al., 2011; Shoaf et al., 2006).

287
288 Recently, it was suggested that pathogen adherence tropism is dependent on three key
289 elements: expression of adhesins; adhesion specificity; and the presence of cognate receptors on
290 the surface of specific tissue culture cells (Korea, Ghigo, & Beloin, 2011). Although the precise
291 mechanism for how CHOS prevent adherence of EPEC to epithelial cells will require further
292 investigation, we suggest that CHOS interferes with adhesion attachment to the cognate ligands.
293 In particular, one of the monomers of CHOS is GlcNAc, which is a common constituent of
294 receptor ligands for many bacterial lectins (Buts et al., 2004; Sharon, 1987; Sharon, 2006).
295 However, the occurrence of non-acetylated glucosamines as a target ligand on the surface of
296 epithelial cells has not been reported. In addition, the present data clearly shows that inhibition
297 of adherence requires an oligomeric carbohydrate (Fig. 3), as free monomeric sugars had no
298 effect on adherence.

299
300 The ability of chitosan polymers to inhibit growth of *E.coli* has been reported previously,
301 (Eaton et al., 2008; Li et al., 2010; Liu et al., 2004), although this effect was observed only for
302 chitosans of higher DP, i.e. higher than the DP of the CHOS used in the present study. Other
303 studies have shown that shorter CHOS, at DP < 20 do not kill *E. coli* (Li et al., 2010; Mellegård
304 et al., 2011). Indeed, growth of EPEC was not impaired by the CHOS used in this study,
305 indicating that reduced adherence of EPEC was not due to growth inhibition or cell killing. Thus,

306 it seems that the anti-adherence effect of CHOS is independent of the other biological effects of
307 CHOS and chitosan.

308

309 In summary, our results show that different fractions of CHOS inhibit adherence of EPEC
310 to the surface of tissue culture cells. Further research is needed to identify the specific CHOS
311 species responsible for the observed inhibition and to assess these effects *in vivo*, i.e., on
312 pathogen adherence in the animal gastrointestinal tract. Finally, other potential biological
313 activities of CHOS, including their possible impact on the intestinal microbiota, should also be
314 considered.

315

316 **Acknowledgements**

317 This work was financed in part by Norwegian Research Council grant number 197388 to BBA.

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333


334

335

336

337 **Figures**

338




339

340


B

F_A 0.15 + ScCsn46A



341

342



343

344

345 **Fig. 1. SEC and MALDI-TOF analysis of hydrolyzed $F_A0.15$ chitosan.** Fig. 1A shows the
 346 size exclusion chromatogram (SEC) of CHOS obtained upon enzymatic hydrolysis of the $F_A0.15$
 347 chitosan with ScCsn46A from *Streptomyces coelicolor* A3(2). Peaks are labeled by the DP of the
 348 oligomers they contain; the region labeled “>12” and “DP_n25” was collected and tested as one
 349 (mixed) fraction. MALDI-TOF-MS analysis was performed on the different SEC fractions. Fig.
 350 1B shows the DP 3-7 fractions and Fig. 1C the DP 8-12 fractions. Major signals are labeled by
 351 mass, sugar composition (A, GlcNAc; D, GlcN) and adduct type (H^+ , Na^+ or K^+).

352



353

354

355

356

357



358

359

360 **Figure 2.** Adherence of EPEC to HEp-2 cells in the presence (B) and absence (A) of CHOS with
361 F_A0.15 at a concentration of 16 mg/ml.

362

363

364

365

366

367

368

369

370

371

372

373

374

375


376

377

378

379

380



381

382

383 **Fig. 3. Inhibition of EPEC adherence to HEp-2 cells by CHOS mixtures with different FA.**

384 Statistical analysis was performed by Analysis of Variance (ANOVA) to determine statistical
385 differences from the control. Tukey's test was used to determine significant differences among
386 the treatments. (n = 4). Values sharing the same letter are not significantly different from each
387 other (p < 0.05).

388

389

390


391

392

393

394

395



396

397

398 **Fig.4. Inhibition of EPEC adherence to HEp-2 cells by purified CHOS fractions with**
 399 **different DP obtained by size-exclusion chromatography of enzymatically hydrolyzed**
 400 **FA0.15 chitosan.** Statistical analysis was performed by Analysis of Variance (ANOVA) to
 401 determine statistical differences from the control. Tukey's test was used to determine significant
 402 differences among the treatments. (n=4). Groups sharing the same letter are not significantly
 403 different from each other ($p < 0.05$).

404


405

406

407

408

409



410

411 **Figure 5 Growth of EPEC in the presence and absence of GlcN and GlcNAc.**The graph
 412 shows the growth curve for EPEC in TSB at 37°C in the absence (“Control”) or in the presence
 413 of added sugars. Sugars tested were GlcN, GlcNAc and a 85:15 mix of GlcN: GlcNAc, at a total
 414 sugar concentration of 16 mg/ml.

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431 **5. References**

- 432 Aam, B. B., Heggset, E. B., Norberg, A. L., Sørli, M., Vårum, K. M., & Eijsink, V. G. H.
433 (2010). Production of chitooligosaccharides and their potential applications in medicine.
434 *Marine drugs*, 8, 1482–517.
- 435 Alishahi, A., & Aïder, M. (2011). Applications of Chitosan in the Seafood Industry and
436 Aquaculture: A Review. *Food and Bioprocess Technology*, 5, 817–830.
- 437 Andersson, B., Porras, O., Hanson, L. A., Lagergard, T., & Svanborg-Eden, C. (1986). Inhibition
438 of Attachment of *Streptococcus pneumoniae* and *Haemophilus influenzae* by Human Milk
439 and Receptor Oligosaccharides. *Journal of Infectious Diseases*, 153, 232–237.
- 440 Bavington, C., & Page, C. (2005). Stopping bacterial adhesion: a novel approach to treating
441 infections. *Respiration. International Review of Thoracic Diseases*, 72, 335–44.
- 442 Benhabiles, M. S., Salah, R., Lounici, H., Drouiche, N., Goosen, M. F. A., & Mameri, N. (2012).
443 Antibacterial activity of chitin, chitosan and its oligomers prepared from shrimp shell waste.
444 *Food Hydrocolloids*, 29, 48–56.
- 445 Bruberg May B., Eijsink Vincent G., Haandrikman Alfred J., Venema Gerard, N. I. F. (1995).
446 Chitinase B from *Serratia marcescens* B JL200 is exported to the periplasm without
447 processing. *Microbiology*, 141, 123–131.
- 448 Buts, L., Bouckaert, J., De Genst, E., Loris, R., Oscarson, S., Lahmann, M., Messens, J., et al.
449 (2004). The fimbrial adhesin F17-G of enterotoxigenic *Escherichia coli* has an
450 immunoglobulin-like lectin domain that binds N-acetylglucosamine. *Molecular*
451 *Microbiology*, 49, 705–715.
- 452 Cravioto, A., Tello, A., Villafan, H., Ruiz, J., del Vedovo, S., & Neeser, J.-R. (1991). Inhibition
453 of Localized Adhesion of Enteropathogenic *Escherichia coli* to HEp-2 Cells by
454 Immunoglobulin and Oligosaccharide Fractions of Human Colostrum and Breast Milk.
455 *Journal of Infectious Diseases*, 163, 1247–1255.
- 456 Devlieghere, F., Vermeulen, a, & Debevere, J. (2004). Chitosan: antimicrobial activity,
457 interactions with food components and applicability as a coating on fruit and vegetables.
458 *Food Microbiology*, 21, 703–714.
- 459 Eaton, P., Fernandes, J. C., Pereira, E., Pintado, M. E., & Malcata, F.X. (2008). Atomic force
460 microscopy study of the antibacterial effects of chitosans on *Escherichia coli* and
461 *Staphylococcus aureus*. *Ultramicroscopy*, 108, 1128–34.
- 462 Ebrahim, G. J. (1997). Editorial. Breastmilk oligosaccharides point the way to new therapeutic
463 strategies. *Journal of Tropical Pediatrics*, 43, 2–3.

- 464 Fernandes, J. C., Eaton, P., Franco, I., Ramos, O. S., Sousa, S., Nascimento, H., Gomes, A., et al.
465 (2012). Evaluation of chitoligosaccharides effect upon probiotic bacteria. *International*
466 *Journal of Biological Macromolecules*, 50, 148–52.
- 467 Ganan, M., Collins, M., Rastall, R., Hotchkiss, A. T., Chau, H. K., Carrascosa, A. V., &
468 Martinez-Rodriguez, A. J. (2010). Inhibition by pectic oligosaccharides of the invasion of
469 undifferentiated and differentiated Caco-2 cells by *Campylobacter jejuni*. *International*
470 *Journal of Food Microbiology*, 137, 181–5.
- 471 Ghosh, S., & Mehla, R. K. (2012). Influence of dietary supplementation of prebiotics
472 (mannanoligosaccharide) on the performance of crossbred calves. *Tropical Animal Health*
473 *and Production*, 44, 617–22.
- 474 Gibson, G. R., & Roberfroid, M. B. (1995). Dietary modulation of the human colonic
475 microbiota: introducing the concept of prebiotics. *The Journal of Nutrition*, 125, 1401–12.
- 476 Haebel, S., Bahrke, S., & Peter, M. G. (2007). Quantitative sequencing of complex mixtures of
477 heterochitooligosaccharides by vMALDI-linear ion trap mass spectrometry. *Analytical*
478 *Chemistry*, 79, 5557–66.
- 479 Heggset, E. B., Hoell, I. A., Kristoffersen, M., Eijsink, V. G. H., & Vårum, K. M. (2009).
480 Degradation of chitosans with chitinase G from *Streptomyces coelicolor* A3(2): production
481 of chito-oligosaccharides and insight into subsite specificities. *Biomacromolecules*, 10,
482 892–9.
- 483 Heggset, E. B., Dybvik, A. I., Hoell, I. A., Norberg, A. L., Sørli, M., Eijsink, V. G. H., &
484 Vårum, K. M. (2010). Degradation of chitosans with a family 46 chitosanase from
485 *Streptomyces coelicolor* A3(2). *Biomacromolecules*, 11, 2487–97.
- 486 Heggset, E. B., Tuveng, T. R., Hoell, I. A., Liu, Z., Eijsink, V. G. H., & Vårum, K. M. (2012).
487 Mode of Action of a Family 75 Chitosanase from *Streptomyces avermitilis*.
488 *Biomacromolecules*, 13, 1733–41.
- 489 Helander, I. M., Nurmiäho-Lassila, E. L., Ahvenainen, R., Rhoades, J., & Roller, S. (2001).
490 Chitosan disrupts the barrier properties of the outer membrane of gram-negative bacteria.
491 *International Journal of Food Microbiology*, 71, 235–44.
- 492 Jayakumar, R., Menon, D., Manzoor, K., Nair, S. V., & Tamura, H. (2010). Biomedical
493 applications of chitin and chitosan based nanomaterials—A short review. *Carbohydrate*
494 *Polymers*, 82, 227–232.
- 495 Kean, T., & Thanou, M. (2010). Biodegradation, biodistribution and toxicity of chitosan.
496 *Advanced Drug Delivery Reviews*, 62, 3–11.
- 497 Klemm, P., Vejborg, R. M., & Hancock, V. (2010). Prevention of bacterial adhesion. *Applied*
498 *Microbiology and Biotechnology*, 88, 451–459–459.

- 499 Korea, C.G., Ghigo, J.M., & Beloin, C. (2011). The sweet connection: Solving the riddle of
500 multiple sugar-binding fimbrial adhesins in Escherichia coli: Multiple E. coli fimbriae form
501 a versatile arsenal of sugar-binding lectins potentially involved in surface-colonisation and
502 tissue tropism. *BioEssays: News and Reviews in Molecular, Cellular and Developmental*
503 *Biology*, 33, 300–11.
- 504 Kunz, C., Rudloff, S., Baier, W., Klein, N., & Strobel, S. (2000). Oligosaccharides in human
505 milk: structural, functional, and metabolic aspects. *Annual review of Nutrition*, 20, 699–722.
- 506 Lee, H.-W., Park, Y.-S., Jung, J.-S., & Shin, W.-S. (2002). Chitosan oligosaccharides, dp 2-8,
507 have prebiotic effect on the Bifidobacterium bifidium and Lactobacillus sp. *Anaerobe*, 8,
508 319–24.
- 509 Li, X., Feng, X., Yang, S., Fu, G., Wang, T., & Su, Z. (2010). Chitosan kills Escherichia coli
510 through damage to be of cell membrane mechanism. *Carbohydrate Polymers*, 79, 493–499.
- 511 Liu, H., Du, Y., Wang, X., & Sun, L. (2004). Chitosan kills bacteria through cell membrane
512 damage. *International Journal of Food Microbiology*, 95, 147–155.
- 513 Mellegård, H., Strand, S. P., Christensen, B. E., Granum, P. E., & Hardy, S. P. (2011).
514 Antibacterial activity of chemically defined chitosans: influence of molecular weight,
515 degree of acetylation and test organism. *International Journal of Food Microbiology*, 148,
516 48–54.
- 517 Muzzarelli, R. (1996). Chitosan-based dietary foods. *Carbohydrate Polymers*, 29, 309–316.
- 518 Muzzarelli, R. A. & Muzzarelli, C. (2005). Chitosan Chemistry: Relevance to the biomedical
519 sciences. In T. Heinze (Ed.). *Polysaccharides I: Structure, Characterization, and Use* (pp.
520 151–209). Berlin: Springer-Verlag Berlin.
- 521 No, H. K., Meyers, S. P., Prinyawiwatkul, W., & Xu, Z. (2007). Applications of chitosan for
522 improvement of quality and shelf life of foods: a review. *Journal of Food Science*, 72, R87–
523 100.
- 524 Ofek, I., & Beachey, E. H. (1978). Mannose Binding and Epithelial Cell Adherence of
525 Escherichia coli. *Infection and Immunity*, 22, 247–254.
- 526 Ofek, I., Hasty, D. L., & Doyle, R. J. (2003). In Ofek, I. & Doyle, R.J. (Ed.). *Bacterial adhesion*
527 *to animal cells and tissues* (p. 416). ASM Press.
- 528 Quintero, M., Maldonado, M., Perez-Munoz, M., Jimenez, R., Fangman, T., Rupnow, J., Wittke,
529 A., et al. (2011). Adherence Inhibition of Cronobacter sakazakii to Intestinal Epithelial
530 Cells by Prebiotic Oligosaccharides. *Current Microbiology*. 62, 1448-1454.
- 531 Rabea, E. I., Badawy, M. E.-T., Stevens, C. V., Smagghe, G., & Steurbaut, W. (2003). Chitosan
532 as antimicrobial agent: applications and mode of action. *Biomacromolecules*, 4, 1457–65.

- 533 Rhoades, J., Gibson, G., Formentin, K., Beer, M., & Rastall, R. (2006). Inhibition of the
534 adhesion of enteropathogenic *Escherichia coli* strains to HT-29 cells in culture by chito-
535 oligosaccharides. *Carbohydrate Polymers*, 64, 57–59.
- 536 Rigby, G. W. (1934). Substantially undegraded deacetylated chitin and process for producing the
537 same. US Patent 2,040,879.
- 538 Roberfroid, M. (2007). Prebiotics: The Concept Revisited. *Journal of Nutrition*, 137, 830S–837.
- 539 Sannan, T., Kurita, K., & Iwakura, Y. (1975). Studies on chitin, 1. Solubility change by alkaline
540 treatment and film casting. *Die Makromolekulare Chemie*, 176, 1191–1195.
- 541 Sharon, N. (1987). Bacterial lectins, cell-cell recognition and infectious disease. *FEBS Letters*,
542 217, 145–57.
- 543 Sharon, N. (2006). Carbohydrates as future anti-adhesion drugs for infectious diseases.
544 *Biochimica et Biophysica Acta*, 1760, 527–37.
- 545 Shoaf, K., Mulvey, G. L., Armstrong, G. D., & Hutkins, R. W. (2006). Prebiotic
546 galactooligosaccharides reduce adherence of enteropathogenic *Escherichia coli* to tissue
547 culture cells. *Infection and Immunity*, 74, 6920–8.
- 548 Simůnek, J., Koppová, I., Filip, L., Tishchenko, G., & Bełzecki, G. (2010). The antimicrobial
549 action of low-molar-mass chitosan, chitosan derivatives and chitooligosaccharides on
550 bifidobacteria. *Folia Microbiologica*, 55, 379–82.
- 551 Sørbotten, A., Horn, S. J., Eijsink, V. G. H., & Vårum, K. M. (2005). Degradation of chitosans
552 with chitinase B from *Serratia marcescens*. Production of chito-oligosaccharides and insight
553 into enzyme processivity. *The FEBS Journal*, 272, 538–49.
- 554 Thanassi, D. G. (2011). The long and the short of bacterial adhesion regulation. *Journal of*
555 *Bacteriology*, 193, 327–8.
- 556 Tsai, G.J., Su, W.H., Chen, H.C., & Pan, C.L. (2002). Antimicrobial activity of shrimp chitin and
557 chitosan from different treatments and applications of fish preservation. *Fisheries Science*,
558 68, 170–177.
- 559 Vårum, K. M., Anthonsen, M. W., Grasdalen, H., & Smidsrød, O. (1991). Determination of the
560 degree of N-acetylation and the distribution of N-acetyl groups in partially N-deacetylated
561 chitins (chitosans) by high-field n.m.r. spectroscopy. *Carbohydrate Research*, 211, 17–23.
- 562 Wu, H., Aam, B. B., Wang, W., Norberg, A. L., Sørli, M., Eijsink, V. G. H., & Du, Y. (2012).
563 Inhibition of angiogenesis by chitooligosaccharides with specific degrees of acetylation and
564 polymerization. *Carbohydrate Polymers*, 89, 511–518.

565 Xia, W., Liu, P., Zhang, J., & Chen, J. (2011). Biological activities of chitosan and
566 chitooligosaccharides. *Food Hydrocolloids*, 25, 170–179.

567